← All Compounds
Mechanism C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). Potent anti-inflammatory activity via NF-kB inhibition and PGE2 reduction. Modulates gut inflammation and mucosal immune response. Half-Life Estimated 30-60 minutes Route subcutaneous Frequency Once daily
FDA Category Research peptide (removed from FDA Category 2) Reclassification removed-from-cat2 Date Restricted 2023-09-29 Announced Return 2026-02-27
Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.
KPV (Lys-Pro-Val)
Removed from Cat 2
Longevity & Immune · Research peptide (multiple suppliers)
Anti-inflammatory tripeptide fragment of alpha-MSH researched for gut and mucosal immune modulation. Not FDA-approved for any indication.
About
Clinical Dosing
200-500 mcgonce daily
Removed from Category 2 by FDA (April 15, 2026). Will be evaluated by PCAC beginning July 2026. Not yet Category 1 — awaiting formal PCAC review.
Dosing extrapolated from animal studies and community protocols. No large-scale human clinical trials.
Regulatory Status
Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.
View full regulatory timeline →Titration Protocols
Research Protocol
Source: Brzoska et al., Endocrine Reviews, 2008
| Dose | Duration | Draw (5 mg vial in 2mL) | Notes |
|---|---|---|---|
| 300 mcg | Maintenance | 0.12 mL (12 units) | Standard research dose |
Available Vial Sizes
5 mg
5 mg vial
10 mg
10 mg vial
Citations
- [1]Alpha-MSH and Related Tripeptides: Biochemistry, Anti-Inflammatory and Protective Effects. Endocrine Reviews, 29(5), 581-602. Link(Reviewed: 2026-02-27)